Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers

results from the PROSIT study

Simone Negrini, Ottavia Magnani, Marco Matucci-Cerinic, Renato Carignola, Valeria Data, Erika Montabone, Alessandro Santaniello, Giuditta Adorni, Giuseppe Murdaca, Francesco Puppo, Francesco Indiveri, Alessandra Della Rossa, Anna D’Ascanio, Simone Barsotti, Dilia Giuggioli, Clodoveo Ferri, Federica Lumetti, Silvia Laura Bosello, Giovanni Canestrari, Silvia Bellando Randone & 6 others Cosimo Bruni, Serena Guiducci, Elisabetta Battaglia, Maria Ilenia De Andres, Alessandra Azzurra Russo, Lorenzo Beretta

Research output: Contribution to journalArticle

Abstract

Vasculopathy is a crucial feature of systemic sclerosis (SSc), and Raynaud’s phenomenon (RP) and digital ulcers (DU) have a deep impact on the quality of patients’ life. The management of vascular disease can be challenging for the clinician because of the suboptimal tolerability of the treatments and lack of consensus on the best therapeutic approach. Intravenous iloprost, a synthetic analogue of prostacyclin, is broadly used for the treatment of RP and ischemic ulcers secondary to SSc. However, no standardized protocol on iloprost use is currently available and, consequently, the management of this treatment is largely based on the experience of each single center. The PROSIT project is an observational, multicenter study aiming to investigate the current treatments for SSc vasculopathy, the use of prostanoids, with special regard to iloprost, and the perception of the treatment from a patient’s perspective. The study was conducted on a cohort of 346 patients from eight Italian centers and included a structured survey addressed to physicians, data collected from patient’s medical records and two patient-administered questionnaires assessing the level of satisfaction, tolerability and perception of the efficacy of Iloprost. PROSIT data confirmed that in the contest of SSc iloprost represents the first-line choice for the management of severe RP and DU. Moreover, it is a well-tolerated treatment as reported by patients’ experience. Although a standard protocol for the treatment of SSc-related vasculopathy is lacking, PROSIT study identified different therapeutic approaches largely supported by tertiary Italian centers. Further studies are needed in order to optimize the best treatment for SSc vascular diseases, in particular to improve the best iloprost schedule management.

Original languageEnglish
Pages (from-to)357-366
JournalClinical and Experimental Medicine
Volume19
Issue number3
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Iloprost
Systemic Scleroderma
Tertiary Care Centers
Raynaud Disease
Ulcer
Therapeutics
Vascular Diseases
Epoprostenol
Prostaglandins
Clinical Protocols
Multicenter Studies
Medical Records
Observational Studies
Consensus
Appointments and Schedules
Quality of Life
Physicians

Keywords

  • Digital ulcers
  • Iloprost
  • PROSIT
  • Raynaud’s phenomenon
  • Systemic sclerosis
  • Vasculopathy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers : results from the PROSIT study. / Negrini, Simone; Magnani, Ottavia; Matucci-Cerinic, Marco; Carignola, Renato; Data, Valeria; Montabone, Erika; Santaniello, Alessandro; Adorni, Giuditta; Murdaca, Giuseppe; Puppo, Francesco; Indiveri, Francesco; Della Rossa, Alessandra; D’Ascanio, Anna; Barsotti, Simone; Giuggioli, Dilia; Ferri, Clodoveo; Lumetti, Federica; Bosello, Silvia Laura; Canestrari, Giovanni; Bellando Randone, Silvia; Bruni, Cosimo; Guiducci, Serena; Battaglia, Elisabetta; De Andres, Maria Ilenia; Russo, Alessandra Azzurra; Beretta, Lorenzo.

In: Clinical and Experimental Medicine, Vol. 19, No. 3, 01.01.2019, p. 357-366.

Research output: Contribution to journalArticle

Negrini, S, Magnani, O, Matucci-Cerinic, M, Carignola, R, Data, V, Montabone, E, Santaniello, A, Adorni, G, Murdaca, G, Puppo, F, Indiveri, F, Della Rossa, A, D’Ascanio, A, Barsotti, S, Giuggioli, D, Ferri, C, Lumetti, F, Bosello, SL, Canestrari, G, Bellando Randone, S, Bruni, C, Guiducci, S, Battaglia, E, De Andres, MI, Russo, AA & Beretta, L 2019, 'Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study', Clinical and Experimental Medicine, vol. 19, no. 3, pp. 357-366. https://doi.org/10.1007/s10238-019-00553-y
Negrini, Simone ; Magnani, Ottavia ; Matucci-Cerinic, Marco ; Carignola, Renato ; Data, Valeria ; Montabone, Erika ; Santaniello, Alessandro ; Adorni, Giuditta ; Murdaca, Giuseppe ; Puppo, Francesco ; Indiveri, Francesco ; Della Rossa, Alessandra ; D’Ascanio, Anna ; Barsotti, Simone ; Giuggioli, Dilia ; Ferri, Clodoveo ; Lumetti, Federica ; Bosello, Silvia Laura ; Canestrari, Giovanni ; Bellando Randone, Silvia ; Bruni, Cosimo ; Guiducci, Serena ; Battaglia, Elisabetta ; De Andres, Maria Ilenia ; Russo, Alessandra Azzurra ; Beretta, Lorenzo. / Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers : results from the PROSIT study. In: Clinical and Experimental Medicine. 2019 ; Vol. 19, No. 3. pp. 357-366.
@article{2c68ed3ff14f479d919c7b3bb7c83c5c,
title = "Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study",
abstract = "Vasculopathy is a crucial feature of systemic sclerosis (SSc), and Raynaud’s phenomenon (RP) and digital ulcers (DU) have a deep impact on the quality of patients’ life. The management of vascular disease can be challenging for the clinician because of the suboptimal tolerability of the treatments and lack of consensus on the best therapeutic approach. Intravenous iloprost, a synthetic analogue of prostacyclin, is broadly used for the treatment of RP and ischemic ulcers secondary to SSc. However, no standardized protocol on iloprost use is currently available and, consequently, the management of this treatment is largely based on the experience of each single center. The PROSIT project is an observational, multicenter study aiming to investigate the current treatments for SSc vasculopathy, the use of prostanoids, with special regard to iloprost, and the perception of the treatment from a patient’s perspective. The study was conducted on a cohort of 346 patients from eight Italian centers and included a structured survey addressed to physicians, data collected from patient’s medical records and two patient-administered questionnaires assessing the level of satisfaction, tolerability and perception of the efficacy of Iloprost. PROSIT data confirmed that in the contest of SSc iloprost represents the first-line choice for the management of severe RP and DU. Moreover, it is a well-tolerated treatment as reported by patients’ experience. Although a standard protocol for the treatment of SSc-related vasculopathy is lacking, PROSIT study identified different therapeutic approaches largely supported by tertiary Italian centers. Further studies are needed in order to optimize the best treatment for SSc vascular diseases, in particular to improve the best iloprost schedule management.",
keywords = "Digital ulcers, Iloprost, PROSIT, Raynaud’s phenomenon, Systemic sclerosis, Vasculopathy",
author = "Simone Negrini and Ottavia Magnani and Marco Matucci-Cerinic and Renato Carignola and Valeria Data and Erika Montabone and Alessandro Santaniello and Giuditta Adorni and Giuseppe Murdaca and Francesco Puppo and Francesco Indiveri and {Della Rossa}, Alessandra and Anna D’Ascanio and Simone Barsotti and Dilia Giuggioli and Clodoveo Ferri and Federica Lumetti and Bosello, {Silvia Laura} and Giovanni Canestrari and {Bellando Randone}, Silvia and Cosimo Bruni and Serena Guiducci and Elisabetta Battaglia and {De Andres}, {Maria Ilenia} and Russo, {Alessandra Azzurra} and Lorenzo Beretta",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s10238-019-00553-y",
language = "English",
volume = "19",
pages = "357--366",
journal = "Zeitschrift fü Die Gesamte Experimentelle Medizin",
issn = "1591-8890",
publisher = "Springer-Verlag Italia",
number = "3",

}

TY - JOUR

T1 - Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers

T2 - results from the PROSIT study

AU - Negrini, Simone

AU - Magnani, Ottavia

AU - Matucci-Cerinic, Marco

AU - Carignola, Renato

AU - Data, Valeria

AU - Montabone, Erika

AU - Santaniello, Alessandro

AU - Adorni, Giuditta

AU - Murdaca, Giuseppe

AU - Puppo, Francesco

AU - Indiveri, Francesco

AU - Della Rossa, Alessandra

AU - D’Ascanio, Anna

AU - Barsotti, Simone

AU - Giuggioli, Dilia

AU - Ferri, Clodoveo

AU - Lumetti, Federica

AU - Bosello, Silvia Laura

AU - Canestrari, Giovanni

AU - Bellando Randone, Silvia

AU - Bruni, Cosimo

AU - Guiducci, Serena

AU - Battaglia, Elisabetta

AU - De Andres, Maria Ilenia

AU - Russo, Alessandra Azzurra

AU - Beretta, Lorenzo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Vasculopathy is a crucial feature of systemic sclerosis (SSc), and Raynaud’s phenomenon (RP) and digital ulcers (DU) have a deep impact on the quality of patients’ life. The management of vascular disease can be challenging for the clinician because of the suboptimal tolerability of the treatments and lack of consensus on the best therapeutic approach. Intravenous iloprost, a synthetic analogue of prostacyclin, is broadly used for the treatment of RP and ischemic ulcers secondary to SSc. However, no standardized protocol on iloprost use is currently available and, consequently, the management of this treatment is largely based on the experience of each single center. The PROSIT project is an observational, multicenter study aiming to investigate the current treatments for SSc vasculopathy, the use of prostanoids, with special regard to iloprost, and the perception of the treatment from a patient’s perspective. The study was conducted on a cohort of 346 patients from eight Italian centers and included a structured survey addressed to physicians, data collected from patient’s medical records and two patient-administered questionnaires assessing the level of satisfaction, tolerability and perception of the efficacy of Iloprost. PROSIT data confirmed that in the contest of SSc iloprost represents the first-line choice for the management of severe RP and DU. Moreover, it is a well-tolerated treatment as reported by patients’ experience. Although a standard protocol for the treatment of SSc-related vasculopathy is lacking, PROSIT study identified different therapeutic approaches largely supported by tertiary Italian centers. Further studies are needed in order to optimize the best treatment for SSc vascular diseases, in particular to improve the best iloprost schedule management.

AB - Vasculopathy is a crucial feature of systemic sclerosis (SSc), and Raynaud’s phenomenon (RP) and digital ulcers (DU) have a deep impact on the quality of patients’ life. The management of vascular disease can be challenging for the clinician because of the suboptimal tolerability of the treatments and lack of consensus on the best therapeutic approach. Intravenous iloprost, a synthetic analogue of prostacyclin, is broadly used for the treatment of RP and ischemic ulcers secondary to SSc. However, no standardized protocol on iloprost use is currently available and, consequently, the management of this treatment is largely based on the experience of each single center. The PROSIT project is an observational, multicenter study aiming to investigate the current treatments for SSc vasculopathy, the use of prostanoids, with special regard to iloprost, and the perception of the treatment from a patient’s perspective. The study was conducted on a cohort of 346 patients from eight Italian centers and included a structured survey addressed to physicians, data collected from patient’s medical records and two patient-administered questionnaires assessing the level of satisfaction, tolerability and perception of the efficacy of Iloprost. PROSIT data confirmed that in the contest of SSc iloprost represents the first-line choice for the management of severe RP and DU. Moreover, it is a well-tolerated treatment as reported by patients’ experience. Although a standard protocol for the treatment of SSc-related vasculopathy is lacking, PROSIT study identified different therapeutic approaches largely supported by tertiary Italian centers. Further studies are needed in order to optimize the best treatment for SSc vascular diseases, in particular to improve the best iloprost schedule management.

KW - Digital ulcers

KW - Iloprost

KW - PROSIT

KW - Raynaud’s phenomenon

KW - Systemic sclerosis

KW - Vasculopathy

UR - http://www.scopus.com/inward/record.url?scp=85064431160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064431160&partnerID=8YFLogxK

U2 - 10.1007/s10238-019-00553-y

DO - 10.1007/s10238-019-00553-y

M3 - Article

VL - 19

SP - 357

EP - 366

JO - Zeitschrift fü Die Gesamte Experimentelle Medizin

JF - Zeitschrift fü Die Gesamte Experimentelle Medizin

SN - 1591-8890

IS - 3

ER -